Tariquidar

Cell lines

KB-3-1, KB-8-5-11 (ABCB1-expressing variant), MCF-7, MCF-7/VP16 (ABCC1-expressing variant), H460, H460/MX20 (ABCG2-expressing variant)

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reaction Conditions

≥ 100 nM

Applications

At concentrations ≥ 100 nM, tariquidar inhibited both P-gp and BCRP but did not inhibit MRP1. Accumulation of the fluorescent substrate calcein-AM in ABCB1-expressing cells treated with 100 nM and 1 μM tariquidar increased 14-fold and 19-fold, respectively. Most P-gp was inhibited at 100 nM. At the same concentrations, tariquidar also increased the accumulation of the fluorescent substrate mitoxantrone in ABCG2-expressing cells by 4-fold (P<0.001) and 8-fold (P<0.001), respectively. These data indicate that tariquidar inhibits both transporters with similar potency because at 100 nM, it restored accumulation to 56% of control for P-gp and 84% of control for BCRP. Tariquidar did not increase accumulation of substrate in ABCC1-expressing cells.

Animal models

NMRI nu/nu mice

Dosage form

Oral administration, 0.1 ml/10 g of body weight

Applications

The ABCB1 modulator tariquidar affects the distribution of paclitaxel in nude mice. In the brains, Co-application of tariquidar with paclitaxel led to a comparable increase in the brain concentration of the cytostatic by a factor of 2.5-to 6.7. In liver, no statistically significant differences were determined between the different ABCB1 modulator group and the control group. In the kidneys, the paclitaxel content in kidney decreased to achieve concentrations similar to those in the untreated control group.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1] Kannan P, Telu S, Shukla S, et al. The “specific” P-glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS chemical neuroscience, 2010, 2(2): 82-89.

[2] Hubensack M, Müller C, Höcherl P, et al. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. Journal of cancer research and clinical oncology, 2008, 134(5): 597-607.